<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02828592</url>
  </required_header>
  <id_info>
    <org_study_id>NSH 1158</org_study_id>
    <nct_id>NCT02828592</nct_id>
  </id_info>
  <brief_title>Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia</brief_title>
  <official_title>A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northside Hospital, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northside Hospital, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe aplastic anemia is a rare and serious form of bone marrow failure related to an
      immune-mediated mechanism that results in severe pancytopenia and high risk for infections
      and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance
      of survival; however, a response rate with just immunosuppression for those patients lacking
      suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of
      patients are cured, 1/3 are dependent on long term immunosuppression, and the other 1/3
      relapse or develop a clonal disorder. Recent studies have shown that using a haploidentical
      donor for transplantation has good response rates and significantly lower rates of acute and
      chronic GVHD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mismatched haploidentical donors will be identified for patients with severe aplastic anemia.
      These patients will undergo a preparative regimen of Fludarabine/Cyclophosphamide/TBI
      followed by haploidentical bone marrow transplantation. Post-transplant Cyclophosphamide will
      be administered on Days 3 &amp; 4. Immunosuppression with Tacrolimus and MMF will begin on Day
      +5; MMF will be discontinued on Day +35 while Tacrolimus continues until Day +180.
      Investigators hypothesize that haploidentical transplantation with the above-mentioned
      preparative regimen will have a &lt;30% graft failure rate. The one-sided exact Binomial test at
      5% significance level will be used to test this hypothesis. The size of 20 patients provides
      the power of 92.5% for confirming the 30-day graft failure rate &lt;30%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrate sustained engraftment after T-cell replete HLA-mismatched haploidentical bone marrow transplantation by collecting chimerism tests monthly following transplant</measure>
    <time_frame>2 years</time_frame>
    <description>Hypothesis is that following preparative regimen and bone marrow transplantation, the 30-day graft failure rate will be &lt;30%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the incidence of regimen-related mortality at 100 days post transplantation by recording treatment-related adverse events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the incidence of grade 2-4 and 3-4 acute graft versus host disease at 100 days post transplantation by assessing signs and symptoms of GVHD throughout post-transplant course</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine incidence of chronic GVHD at 6 months and 1 year post transplantation by assessing signs and symptoms of GVHD throughout post-transplant course</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate overall survival at 100 days and 1 year post transplantation by collecting survival information at those time points</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Flu/Cy/TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine, Cyclophosphamide, TBI followed by bone marrow transplantation. Post-transplant Cyclophosphamide will be on Days 3 &amp; 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m2 IV QD x 5 days (Days -6 to -2)</description>
    <arm_group_label>Flu/Cy/TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>14.5 mg/kg/day IV x 2 doses (Days -6 &amp; -5)</description>
    <arm_group_label>Flu/Cy/TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>300 cGy x1 dose (Day -1)</description>
    <arm_group_label>Flu/Cy/TBI</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabbit ATG</intervention_name>
    <description>1.5 mg/kg/day x 3 days (Days -3 to -1)</description>
    <arm_group_label>Flu/Cy/TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Post-transplant: 50 mg/kg IV QD (Day +3 to +4)</description>
    <arm_group_label>Flu/Cy/TBI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Availability of 3/6 - 5/6 matched (HLA-A, B, DR) related donor who must have negative
             HLA cross-match in the host vs. graft direction

          -  Age &lt;= 65 years for previously treated and &lt;= 75 years for previously treated patients

          -  KPS &gt;= 70%

          -  Aplastic Anemia that meets the following criteria:

        Peripheral Blood (must fulfill 2 of 3):

          -  &lt;500 PMN/mm3

          -  &lt;20,000 platelets

          -  absolute reticulocyte count &lt;40,000/microL

        Bone Marrow (must be either):

          -  markedly hypocellular (&lt;25% of normal cellularity)

          -  moderately hypocellular with 70% non-myeloid precursors and patient meets peripheral
             blood criteria above

        Exclusion Criteria:

          -  poor cardiac function (LVEF &lt;40%)

          -  poor pulmonary function (FEV1 &amp; FVC &lt;50% predicted)

          -  poor liver function (bili &gt;= 2mg/dL)

          -  poor renal function (creatinine &gt;= 2.0mg/dL or creatinine clearance &lt;40mL/min)

          -  prior allogeneic transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melhem Solh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood and Marrow Transplant Group of Georgia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melhem Solh, MD</last_name>
    <phone>404-255-1930</phone>
    <email>msolh@bmtga.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stacey Brown</last_name>
    <phone>404-851-8238</phone>
    <email>stacey.brown@northside.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Blood and Marrow Transplant Group of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melhem Solh, MD</last_name>
      <phone>404-255-1930</phone>
      <email>msolh@bmtga.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melhem Solh, MD</last_name>
      <phone>404-255-1930</phone>
      <email>msolh@bmtga.com</email>
    </contact>
    <contact_backup>
      <last_name>Stacey Brown</last_name>
      <phone>404-851-8238</phone>
      <email>stacey.brown@northside.com</email>
    </contact_backup>
    <investigator>
      <last_name>Scott Solomon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>H. Kent Holland, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asad Bashey, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lawrence Morris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melhem Solh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brodsky RA, Chen AR, Dorr D, Fuchs EJ, Huff CA, Luznik L, Smith BD, Matsui WH, Goodman SN, Ambinder RF, Jones RJ. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010 Mar 18;115(11):2136-41. doi: 10.1182/blood-2009-06-225375. Epub 2009 Dec 16.</citation>
    <PMID>20018919</PMID>
  </reference>
  <results_reference>
    <citation>Socié G. Allogeneic BM transplantation for the treatment of aplastic anemia: current results and expanding donor possibilities. Hematology Am Soc Hematol Educ Program. 2013;2013:82-6. doi: 10.1182/asheducation-2013.1.82. Review.</citation>
    <PMID>24319167</PMID>
  </results_reference>
  <results_reference>
    <citation>Young NS. Current concepts in the pathophysiology and treatment of aplastic anemia. Hematology Am Soc Hematol Educ Program. 2013;2013:76-81. doi: 10.1182/asheducation-2013.1.76. Review.</citation>
    <PMID>24319166</PMID>
  </results_reference>
  <results_reference>
    <citation>Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012 Aug 9;120(6):1185-96. doi: 10.1182/blood-2011-12-274019. Epub 2012 Apr 19. Review.</citation>
    <PMID>22517900</PMID>
  </results_reference>
  <results_reference>
    <citation>Bashey A, Zhang X, Jackson K, Brown S, Ridgeway M, Solh M, Morris LE, Holland HK, Solomon SR. Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index. Biol Blood Marrow Transplant. 2016 Jan;22(1):125-33. doi: 10.1016/j.bbmt.2015.09.002. Epub 2015 Sep 7.</citation>
    <PMID>26359881</PMID>
  </results_reference>
  <results_reference>
    <citation>Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Biol Blood Marrow Transplant. 2015 Jul;21(7):1299-307. doi: 10.1016/j.bbmt.2015.03.003. Epub 2015 Mar 19.</citation>
    <PMID>25797174</PMID>
  </results_reference>
  <results_reference>
    <citation>Bashey A, Solomon SR. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant. 2014 Aug;49(8):999-1008. doi: 10.1038/bmt.2014.62. Epub 2014 May 19. Review.</citation>
    <PMID>24842530</PMID>
  </results_reference>
  <results_reference>
    <citation>Rozman C, Marín P, Nomdedeu B, Montserrat E. Criteria for severe aplastic anaemia. Lancet. 1987 Oct 24;2(8565):955-7.</citation>
    <PMID>2889870</PMID>
  </results_reference>
  <results_reference>
    <citation>Atta EH, de Sousa AM, Schirmer MR, Bouzas LF, Nucci M, Abdelhay E. Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia. Biol Blood Marrow Transplant. 2012 Dec;18(12):1876-82. doi: 10.1016/j.bbmt.2012.07.004. Epub 2012 Jul 11.</citation>
    <PMID>22796534</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SAA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

